IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Cervical cancer remains an important health problem worldwide. Poor tumor oxygenation (hypoxia) is associated with inferior survival in cervical cancer and resistance to radiation treatment. Hypoxia-modifying therapies improve survival, but existing therapies are impractical and/or toxic. Metformin, a non-toxic drug for diabetes, has been shown to decrease tumor hypoxia in animal studies and its use is associated with better survival in diabetic cancer patients. It is hypothesized that metformin may decrease cervical tumor hypoxia and thereby improve tumor response to radiation and survival in patients with locally advanced cervix cancer.
This is a randomized, multicenter phase II study of standard chemoradiation in combination with metformin versus standard chemoradiation alone in women with locally advanced cervix cancer. Women randomized to the metformin group will take metformin starting 1 week prior to standard chemoradiation and throughout the duration of external radiation treatment. Tumor hypoxia will be measured by a special X-ray test called positron emission test (PET) performed with a hypoxia dye called FAZA. The main purpose of this study is to see if metformin decreases tumor hypoxia measured on FAZA-PET; information about response and side effects will also be collected.
| Condition | Intervention | Phase |
|---|---|---|
| Uterine Cervical Neoplasms Squamous Cell Carcinoma Adenocarcinoma Carcinoma, Adenosquamous | Drug: Metformin Drug: Cisplatin Drug: FAZA | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial |
- • Change in fractional hypoxic volume of the tumor on FAZA-PET scan before and after 1 week of metformin. [ Time Frame: About 7 days ]
- Disease-free survival [ Time Frame: 2 years ]
- Acute and late gastrointestinal and genitourinary toxicities following metformin and chemoradiation. [ Time Frame: 2 years ]
- Effect of metformin on endogenous hypoxia and other markers. [ Time Frame: About 7 days ]
- Biomarkers of response to metformin. [ Time Frame: 2 years ]
| Estimated Enrollment: | 48 |
| Study Start Date: | May 2015 |
| Estimated Study Completion Date: | May 2018 |
| Estimated Primary Completion Date: | October 2017 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Experimental: Metformin with Standard Chemoradiation
Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation. Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation. FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation) |
Drug: Metformin
Drug: Cisplatin
Drug: FAZA
Other Name: 18F-Fluoroazomycin arabinoside
|
|
Active Comparator: Standard Chemoradiation
Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation. FAZA-PET scan at baseline and about 1 week later (just prior to the start of chemoradiation). |
Drug: Cisplatin
Drug: FAZA
Other Name: 18F-Fluoroazomycin arabinoside
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IB2-IVA
- Planned for radical radiotherapy and concurrent cisplatin chemotherapy.
- Able to receive weekly cisplatin.
- No prior anticancer treatment for cervical cancer
- ECOG 0 or 1
- Life expectancy of greater than 3 months.
- Normal organ and marrow function
- Able to take oral medications.
- Ability to understand and willing to sign the consent form
- Willing to undergo biopsies of cervical tumor.
Exclusion Criteria:
- Evidence of distant metastases
- Receiving any other investigational agents concurrently or within 4 weeks.
- Known diabetes mellitus.
- Currently taking metformin, sulfonylureas, thiazolidinediones or insulin.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or cisplatin.
- Any condition associated with increased risk of metformin-associated lactic acidosis
- Uncontrolled inter-current illness
- Pregnant women
- History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for >=5 years.
- Known HIV-positive
- History of bowel obstruction or malabsorption syndromes
- History of active clinically significant bleeding
- Contraindications to radiotherapy
- Taking drug disulfiram (antabuse).
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT02394652
| Contact: Kathy Han, M.D., M.Sc. | 416-946-2919 |
| Canada, Alberta | |
| Tom Baker Cancer Centre | Not yet recruiting |
| Calgary, Alberta, Canada, T2N 4N2 | |
| Contact: Corinne Doll, M.D. 403-521-3685 | |
| Cross Cancer Institute | Not yet recruiting |
| Edmonton, Alberta, Canada, T6G 1Z2 | |
| Contact: Ericka Wiebe, M.D. 480-432-8755 | |
| Canada, Ontario | |
| Princess Margaret Cancer Centre | Recruiting |
| Toronto, Ontario, Canada, M5G 2M9 | |
| Contact: Kathy Han, M.D., M.Sc. 416-946-2919 | |
| Canada, Quebec | |
| Hôpital Maisonneuve-Rosemont | Not yet recruiting |
| Montréal, Quebec, Canada, H1T 2M4 | |
| Contact: Eve-Lyne Marchand, M.D., Ph.D. 514-252-3425 | |
| Centre Hospitalier De L'Université de Montréal | Not yet recruiting |
| Montréal, Quebec, Canada, H2L 4M1 | |
| Contact: Maroie Barkati, M.D. 514-890-8000 ext 28820 | |
| Principal Investigator: | Kathy Han, M.D. | Princess Margaret Cancer Centre |
More Information
| Responsible Party: | University Health Network, Toronto |
| ClinicalTrials.gov Identifier: | NCT02394652 History of Changes |
| Other Study ID Numbers: |
CXMET1 |
| Study First Received: | March 16, 2015 |
| Last Updated: | June 21, 2016 |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Squamous Cell Adenocarcinoma Uterine Cervical Neoplasms Carcinoma, Adenosquamous Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Uterine Neoplasms Genital Neoplasms, Female |
Urogenital Neoplasms Neoplasms by Site Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female Neoplasms, Complex and Mixed Cisplatin Metformin Antineoplastic Agents Hypoglycemic Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 22, 2017